Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of breast cancer
• * Stage I, II, or IIIA disease
• Completed ≤ 6 years of adjuvant tamoxifen therapy
• Total baseline lumbar spine or femoral neck bone mineral density T-score below -2.0 standard deviation (e.g., a patient with a T-score of -2.1 in ineligible; a patient with a T-score of -1.9 is eligible)
• No clinical or radiological evidence of recurrent or metastatic disease
• Hormone receptor status:
• * Estrogen receptor- and/or progesterone receptor-positive
• PATIENT CHARACTERISTICS:
• Age
• Postmenopausal
• Sex
• Female
• Menopausal status
• Postmenopausal, defined by 1 of the following:
• * Over 55 years of age with cessation of menses
• * 55 years of age and under with spontaneous cessation of menses for \> 1 year
• * 55 years of age and under with spontaneous cessation of menses for ≤ 1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy) with postmenopausal estradiol levels (\< 5 ng/dL)
• * Undergone bilateral oophorectomy
• Performance status
• ECOG 0-2
• Life expectancy
• At least 5 years
• Hematopoietic
• WBC ≥ 3,000/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)
• AST ≤ 3 times ULN
• Renal
• Creatinine \< 2.0 mg/dL
• No hypercalcemia (i.e., calcium \> 1 mg/dL above ULN within the past 6 months)
• No hypocalcemia (i.e., calcium \> 0.5 mg/dL below lower limit of normal within the past 6 months)
• Other
• No uncontrolled infection
• No uncontrolled diabetes mellitus
• No uncontrolled thyroid dysfunction
• No disease affecting bone metabolism (e.g., hyperparathyroidism, hypercortisolism, Paget's disease, or osteogenesis imperfecta)
• No malabsorption syndrome
• No uncontrolled seizure disorder associated with falls
• No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or cholecalciferol (vitamin D)
• No mental illness that would preclude giving informed consent
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No other non-malignant systemic disease
• No clinical or radiologic evidence of existing fracture in the lumbar spine and/or total hip
• No history of fracture with low intensity or not associated with trauma
• No contraindication to spinal dual energy x-ray absorptiometry (DEXA) due to any of the following:
• * History of surgery at the lumbosacral spine, with or without implantable devices
• * Scoliosis with a Cobb angle \> 15° at the lumbar spine
• * Immobility, hyperostosis, or sclerotic changes at the lumbar spine
• * Evidence of sufficient sclerotic abdominal aorta that would interfere with DEXA scan
• * Any disease of the spine that would preclude proper acquisition of a lumbar spine DEXA
• Considered reliable
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No concurrent chemotherapy
• Endocrine therapy
• See Disease Characteristics
• Prior parathyroid hormone allowed provided it was not administered for \> 1 week
• More than 6 months since prior anabolic steroids or growth hormone
• More than 12 months since prior endocrine therapy (including estrogen) except for the following:
• * Tamoxifen
• * Insulin
• * Oral hypoglycemics
• * Thyroid hormone
• * Steroid inhalers
• More than 12 months since prior systemic corticosteroids except short-term corticosteroids to prevent or treat chemotherapy-induced nausea and vomiting or acute respiratory illness
• * Concurrent short-term corticosteroids allowed
• No other concurrent hormonal therapy
• No concurrent parathyroid hormone
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• Prior systemic sodium fluoride allowed provided it was not administered for \> 3 months within the past 2 years
• More than 3 weeks since prior oral bisphosphonates
• More than 2 weeks since prior and no concurrent drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate)
• More than 30 days since prior systemic investigational drugs and/or devices
• More than 7 days since prior topical investigational drugs
• No prior IV bisphosphonates
• No prior aromatase inhibitor therapy
• No concurrent calcitonin, sodium fluoride, or Tibolone
• No other concurrent anticancer therapy
• No other concurrent bisphosphonates
• No other concurrent investigational drugs or devices